Novel Therapeutic Targets in Severe Shock Treatment

Severe or irreversible shock is a final stage of shock. After treatment of severe shock still exist persistent low microcirculatory perfusion, refractory hypotension, and cell injury, which are 3 main pathogenesis factors and should be looking for new approach to treat it. It has shown that some new therapeutic targets are related to the treatment of the 3 factors, which includes pulse pressure with persistent low perfusion, ASMCs hyperpolarization with refractory hypotension, mitochondrial dysfunction with cell injury, SIRT1 activity with mitochondrial dysfunction. A new anti- shock medicine-polyda-tin has effected on these new therapeutic targets, which has been going to clinical trial in China and America.